代谢综合征与膀胱癌风险：队列研究的荟萃分析。
完整摘要 · 中文译文
背景：本研究旨在系统评估代谢综合征（MetS）与膀胱癌发病率之间的关系。 方法：我们对PubMed、EMBASE、Cochrane CENTRAL、Web of Science和Scopus数据库进行了全面检索，以获取符合条件的队列研究。采用随机效应模型估计合并相对危险度（RR）及相应的95%置信区间（CI）。通过留一法敏感性分析检验稳健性。发表偏倚通过图形法（漏斗图）和统计法（Begg检验和Egger检验）进行评估。 结果：最终荟萃分析纳入六项研究，涵盖总人口超过1300万个体和22,000例新诊断病例。汇总数据显示，MetS与膀胱癌风险统计学显著升高12%相关（RR = 1.12；95% CI：1.03-1.22）。敏感性分析证明了这些结果的稳定性，未观察到显著发表偏倚的证据。研究间观察到 substantial 异质性（I2 = 62.4%，p = 0.009）。敏感性分析证明了合并估计的稳健性。排除任何单项研究均未实质性改变总体结论。Begg检验的p值为0.711，而Egger检验的p值为0.062。 结论：MetS与膀胱癌发生风险中度升高相关。这些结果强调了维持代谢健康作为膀胱癌预防潜在策略的重要性。
完整摘要 · 英文原文
BACKGROUND: This study aimed to systematically assess the relationship between metabolic syndrome (MetS) and the incidence of bladder cancer. METHODS: We performed a comprehensive search of the PubMed, EMBASE, Cochrane CENTRAL, Web of Science, and Scopus databases to retrieve eligible cohort studies. Pooled relative risk (RR) and corresponding 95% confidence interval (CI) were estimated using a random-effects model. Robustness was checked via a leave-one-out sensitivity analysis. Publication bias was assessed both graphically (funnel plots) and statistically (Begg's and Egger's tests). RESULTS: The final meta-analysis incorporated six studies, encompassing a total population of over 13 million individuals and 22,000 newly diagnosed cases. The aggregated data revealed that MetS was associated with a statistically significant 12% elevation in bladder cancer risk (RR = 1.12; 95% CI: 1.03-1.22). Sensitivity analysis demonstrated the stability of these results, and no evidence of significant publication bias was observed. Substantial heterogeneity was observed across studies (I2 = 62.4%, p = 0.009). Sensitivity analysis demonstrated the robustness of the pooled estimate. Exclusion of any single study did not materially alter the overall conclusion. Begg's test produced a p-value of 0.711, while Egger's test showed a p-value of 0.062. CONCLUSIONS: MetS is linked to a moderately higher risk of developing bladder cancer. These results underscore the importance of maintaining metabolic health as a potential strategy for bladder cancer prevention.